AGEN Agenus Inc
-
Agenus Missed Consensus Estimates
Friday, August 7, 2026 · 12:00 AM ET
Agenus (AGEN) reported a loss of $0.01 per share on revenue of $34.52 million for the second quarter ended June 2026. The consensus earnings estimate was $0.05 per share on revenue of $34.00 million. The company missed consensus estimates by 120.00% while revenue grew 34.31% on a year-over-year basis.
Agenus Inc along with its subsidiaries is a
biopharmaceutical company. The Company is engaged in developing and
commercializing technologies to treat cancers and degenerative disorders.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.01)
Earnings Whisper®
—
Consensus Estimate
$0.05
Earnings Surprise
Earnings Growth
Reported Revenue
$34.52M
Revenue Estimate
$34.00M
Revenue Surprise
Revenue Growth